Literature DB >> 33419306

Nickel Sensitivity Is Associated with GH-IGF1 Axis Impairment and Pituitary Abnormalities on MRI in Overweight and Obese Subjects.

Renata Risi1, Simonetta Masieri2, Eleonora Poggiogalle1, Mikiko Watanabe1, Alessandra Caputi1, Rossella Tozzi1, Elena Gangitano1, Davide Masi1, Stefania Mariani1, Lucio Gnessi1, Carla Lubrano1.   

Abstract

Nickel (Ni) is a ubiquitous metal, the exposure of which is implied in the development of contact dermatitis (nickel allergic contact dermatitis (Ni-ACD)) and Systemic Ni Allergy Syndrome (SNAS), very common among overweight/obese patients. Preclinical studies have linked Ni exposure to abnormal production/release of Growth Hormone (GH), and we previously found an association between Ni-ACD/SNAS and GH-Insulin-like growth factor 1 (IGF1) axis dysregulation in obese individuals, altogether suggesting a role for this metal as a pituitary disruptor. We herein aimed to directly evaluate the pituitary gland in overweight/obese patients with signs/symptoms suggestive of Ni allergy, exploring the link with GH secretion; 859 subjects with overweight/obesity and suspected of Ni allergy underwent Ni patch tests. Among these, 106 were also suspected of GH deficiency (GHD) and underwent dynamic testing as well as magnetic resonance imaging for routine follow up of benign diseases or following GHD diagnosis. We report that subjects with Ni allergies show a greater GH-IGF1 axis impairment, a higher prevalence of Empty Sella (ES), a reduced pituitary volume and a higher normalized T2 pituitary intensity compared to nonallergic ones. We hypothesize that Ni may be detrimental to the pituitary gland, through increased inflammation, thus contributing to GH-IGF1 axis dysregulation.

Entities:  

Keywords:  growth hormone deficiency; nickel sensitivity; obesity; pituitary morphology

Mesh:

Substances:

Year:  2020        PMID: 33419306      PMCID: PMC7766406          DOI: 10.3390/ijms21249733

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  69 in total

1.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update.

Authors:  David M Cook; Kevin C J Yuen; Beverly M K Biller; Stephen F Kemp; Mary Lee Vance
Journal:  Endocr Pract       Date:  2009 Sep-Oct       Impact factor: 3.443

Review 2.  DIAGNOSIS OF ENDOCRINE DISEASE: Primary empty sella: a comprehensive review.

Authors:  S Chiloiro; A Giampietro; A Bianchi; T Tartaglione; A Capobianco; C Anile; L De Marinis
Journal:  Eur J Endocrinol       Date:  2017-08-05       Impact factor: 6.664

3.  Sarcopenic Obesity and Metabolic Syndrome in Adult Caucasian Subjects.

Authors:  E Poggiogalle; C Lubrano; G Sergi; A Coin; L Gnessi; S Mariani; A Lenzi; L M Donini
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

4.  From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis.

Authors:  Isabella Lupi; Jiangyang Zhang; Angelika Gutenberg; Melissa Landek-Salgado; Shey-Cherng Tzou; Susumu Mori; Patrizio Caturegli
Journal:  Endocrinology       Date:  2011-08-23       Impact factor: 4.736

5.  In vivo assessment of pituitary gland volume with magnetic resonance imaging: the effect of age.

Authors:  S N Lurie; P M Doraiswamy; M M Husain; O B Boyko; E H Ellinwood; G S Figiel; K R Krishnan
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

6.  Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study.

Authors:  Carla Lubrano; Marta Tenuta; Daniela Costantini; Palma Specchia; Giuseppe Barbaro; Sabrina Basciani; Stefania Mariani; Alfredo Pontecorvi; Andrea Lenzi; Lucio Gnessi
Journal:  Endocrine       Date:  2015-01-23       Impact factor: 3.633

7.  Functional Toll-like receptor 4 expressed in lactotrophs mediates LPS-induced proliferation in experimental pituitary hyperplasia.

Authors:  María Eugenia Sabatino; Liliana Del Valle Sosa; Juan Pablo Petiti; Jorge Humberto Mukdsi; Iván Darío Mascanfroni; Claudia Gabriela Pellizas; Silvina Gutiérrez; Alicia Inés Torres; Ana Lucía De Paul
Journal:  Exp Cell Res       Date:  2013-08-20       Impact factor: 3.905

8.  Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome.

Authors:  Carla Lubrano; Maurizio Saponara; Giuseppe Barbaro; Palma Specchia; Eliana Addessi; Daniela Costantini; Marta Tenuta; Gabriella Di Lorenzo; Giuseppe Genovesi; Lorenzo M Donini; Andrea Lenzi; Lucio Gnessi
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 9.  Obesity and metabolic comorbidities: environmental diseases?

Authors:  Carla Lubrano; Giuseppe Genovesi; Palma Specchia; Daniela Costantini; Stefania Mariani; Elisa Petrangeli; Andrea Lenzi; Lucio Gnessi
Journal:  Oxid Med Cell Longev       Date:  2013-03-18       Impact factor: 6.543

Review 10.  Trace Elements in Human Nutrition (II) - An Update.

Authors:  Aliasgharpour Mehri
Journal:  Int J Prev Med       Date:  2020-01-03
View more
  2 in total

1.  Growth Hormone Secretory Capacity Is Associated with Cardiac Morphology and Function in Overweight and Obese Patients: A Controlled, Cross-Sectional Study.

Authors:  Elena Gangitano; Giuseppe Barbaro; Martina Susi; Rebecca Rossetti; Maria Elena Spoltore; Davide Masi; Rossella Tozzi; Stefania Mariani; Lucio Gnessi; Carla Lubrano
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

2.  Application of a Machine Learning Technology in the Definition of Metabolically Healthy and Unhealthy Status: A Retrospective Study of 2567 Subjects Suffering from Obesity with or without Metabolic Syndrome.

Authors:  Davide Masi; Renata Risi; Filippo Biagi; Daniel Vasquez Barahona; Mikiko Watanabe; Rita Zilich; Gabriele Gabrielli; Pierluigi Santin; Stefania Mariani; Carla Lubrano; Lucio Gnessi
Journal:  Nutrients       Date:  2022-01-15       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.